'Pivlaz Inj' makes another attempt to be reimb in KOR

By Lee, Tak-Sun | translator Hong, Ji Yeon

25.01.03 05:30:18

가나다라 0

New drug for the prevention of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage…received marketing authorization in December 2023

The company withdrew the reimbursement application in June 2024…it is making another attempt at reimbursement after strengthening the document

'Pivlaz Inj,' which is supplied·distributed in South Korea by Handok, has been submitted for another attempt at reimbursement.

The marketing authorization for Pivlaz was approved in South Korea in December 2023. Then, the company applied for reimbursement but voluntarily withdrew the reimbursement application in June 2024.

According to industry sources on January 2, the reimbursement application for Pivlaz Inj (clazosentan disodium) was submitted to the Health Insurance Review and Assessment Service (HIRA).

Pivlaz Inj, a selective endothelin receptor antagonist, received Korean marketing authorization on December 7, 2023, for the indication to prevent cerebral vasospasm,

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)